Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
J Biol Chem. 2022 Jul;298(7):102079. doi: 10.1016/j.jbc.2022.102079. Epub 2022 May 26.
Dengue viruses (DENV serotypes 1-4) and Zika virus (ZIKV) are related flaviviruses that continue to be a public health concern, infecting hundreds of millions of people annually. The traditional live-attenuated virus vaccine approach has been challenging for the four DENV serotypes because of the need to achieve balanced replication of four independent vaccine components. Subunit vaccines represent an alternative approach that may circumvent problems inherent with live-attenuated DENV vaccines. In mature virus particles, the envelope (E) protein forms a homodimer that covers the surface of the virus and is the major target of neutralizing antibodies. Many neutralizing antibodies bind to quaternary epitopes that span across both E proteins in the homodimer. For soluble E (sE) protein to be a viable subunit vaccine, the antigens should be easy to produce and retain quaternary epitopes recognized by neutralizing antibodies. However, WT sE proteins are primarily monomeric at conditions relevant for vaccination and exhibit low expression yields. Previously, we identified amino acid mutations that stabilize the sE homodimer from DENV2 and dramatically raise expression yields. Here, we tested whether these same mutations raise the stability of sE from other DENV serotypes and ZIKV. We show that the mutations raise thermostability for sE from all the viruses, increase production yields from 4-fold to 250-fold, stabilize the homodimer, and promote binding to dimer-specific neutralizing antibodies. Our findings suggest that these sE variants could be valuable resources in the efforts to develop effective subunit vaccines for DENV serotypes 1 to 4 and ZIKV.
登革热病毒(DENV 血清型 1-4)和 Zika 病毒(ZIKV)是相关的黄病毒,它们继续是公共卫生关注的问题,每年感染数亿人。由于需要实现四种独立疫苗成分的平衡复制,传统的减毒活病毒疫苗方法对于四种 DENV 血清型来说具有挑战性。亚单位疫苗代表了一种替代方法,可以避免减毒 DENV 疫苗固有的问题。在成熟的病毒粒子中,包膜(E)蛋白形成同源二聚体,覆盖病毒表面,是中和抗体的主要靶标。许多中和抗体结合跨越同源二聚体中两个 E 蛋白的四级表位。为了使可溶性 E(sE)蛋白成为可行的亚单位疫苗,抗原应该易于生产并保留中和抗体识别的四级表位。然而,WT sE 蛋白在与疫苗接种相关的条件下主要是单体,表达产量低。先前,我们鉴定了稳定 DENV2 中的 sE 同源二聚体的氨基酸突变,并显著提高了表达产量。在这里,我们测试了这些相同的突变是否会提高来自其他 DENV 血清型和 ZIKV 的 sE 的稳定性。我们表明,这些突变提高了所有病毒的热稳定性,使产量从 4 倍增加到 250 倍,稳定了同源二聚体,并促进与二聚体特异性中和抗体的结合。我们的研究结果表明,这些 sE 变体可能是开发针对 DENV 血清型 1 至 4 和 ZIKV 的有效亚单位疫苗的努力中的有价值资源。